MTOR and breast cancer: Of note, a significant portion of HR+ breast cancers shows dysregulation of the phosphoinositide 3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling, which is also the main contributor to ET resistance [43, 44].